• A rapid test to detect thrombin inhibition by dabigatran would be valuable in acute situations.
• A rapid test to detect thrombin inhibition by dabigatran would be valuable in acute situations.
• A thrombin-based trigger was applied in whole blood using rotation thromboelastometry.
• Effects of dabigatran were assessed in vitro and in samples from patients on dabigatran.
• The test produced data rapidly and was sensitive to dabigatran concentrations from 20 to 500 ng mL À1 .
Summary. Background: Rapid determination of the anticoagulant effect of dabigatran is essential in emergency situations. Objective: To study a viscoelastic test (rotational thromboelastometry [ROTEM] ) for rapid determination of dabigatran effects in whole blood samples. Method: ROTEM measurements were performed with comparison of two triggers (thrombin-based versus the commercial tissue factor-based trigger Ex-tem) in samples from 10 healthy donors spiked with dabigatran (20-500 ng mL
À1
) and in samples from 35 patients receiving dabigatran treatment; 10 healthy subjects served as controls. Clotting time (CT) and the difference in CT without versus with addition of the dabigatran antidote idarucizumab (CT diff ) were measured. Addition of idarucizumab reveals the contribution of dabigatran to ROTEM measurements and its potential reversibility. Results: In vitro studies showed that thrombin CT and thrombin CT diff were more sensitive than Ex-tem CT and Ex-tem CT diff in detecting dabigatran in whole blood samples. In patient samples, when thrombin CT and thrombin CT diff were used, it was possible to detect dabigatran with a cut-off of dabigatran at 20 ng mL
Introduction
The direct thrombin inhibitor dabigatran, which is ingested as the prodrug dabigatran etexilate, was the first of the direct-acting oral anticoagulants (DOACs) to be registered for clinical use. Dabigatran and the other DOACs are rapidly replacing warfarin as the treatment of choice for atrial fibrillation (AF) and venous thromboembolism [1, 2] . One major advantage of dabigatran and other DOACs as compared with warfarin is that no routine testing is required, but there are certain situations, such as bleeding, urgent invasive procedures, thrombosis, and thrombolysis, in which assessment of the anticoagulant activity is helpful [3] . These are fairly common situations -in the pivotal RE-LY trial, the rates of major bleeding and urgent surgery were approximately 3% and 1% per year, respectively [4] . Real-world data have shown a major bleeding rate of 4% per year [5] . Notably, one advantage of dabigatran as compared with the other DOACs is that there is an effective antidote available, i.e. idarucizumab [6] , to reverse dabigatran effects in emergency situations.
Routine coagulation tests (i.e. prothrombin time International Normalized Ratio and activated partial thromboplastin time) may, however, be inadequate for sensitive determination of dabigatran anticoagulation, as these tests provide only an approximation of activity [7] [8] [9] [10] . Actual dabigatran concentrations can be determined directly with high sensitivity by the use of liquid chromatography with tandem mass spectrometry (LC-MS/ MS), which measures free unconjugated dabigatran and is the 'gold standard' method, but also indirectly with special plasma-based functional coagulation assays, in which coagulation is triggered with thrombin or ecarin (e.g. diluted thrombin time and ecarin chromogenic assays) [7, 8, 11, 12] . However, with these methods it may take 30 min to several hours before a test result can be delivered to the clinician. This may affect decisions regarding treatment and antidote administration.
There is growing interest in using viscoelastic methods such as rotational thromboelastometry [ROTEM]) or thromboelastography) to detect ongoing treatment with DOACs [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . These instruments are used in intensive care units and surgical wards worldwide to guide transfusions in perioperative and trauma settings [32] . We recently showed that, in samples from patients with AF, ROTEM clotting time (CT) correlated strongly with dabigatran concentration as measured with LC-MS/MS [33] . Different triggers are used in the ROTEM assay, and the correlation with dabigatran concentration varied with the trigger used. The best correlations were found with commercial tissue factor (TF)-based triggers, but even with these triggers CT could be close to or within the normal value in patients receiving dabigatran treatment [33] .
The aim of this study was to evaluate whether the point-of-care system comprising ROTEM with a thrombin-based trigger improves the determination of dabigatran effects in whole blood samples from patients receiving dabigatran treatment.
Materials and methods

Patients, donors, and handling of blood samples
The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Ethical Review Board in Stockholm, Sweden ( Patients' samples were analyzed for plasma dabigatran concentrations with LC-MS/MS as previously described [7] . In addition, hemoglobin concentrations, venous platelet counts and serum creatinine levels were measured in patient samples according to routine, at the Karolinska University Laboratory.
In the first part of the study (in vitro study), whole blood was obtained from 10 healthy blood donors. Aliquots of 1.5 mL of whole blood were incubated at 37°C for 15 min with 15 lL of dabigatran diluted in DMSO at concentrations calculated to give final plasma concentrations of 0, 20, 50, 100, 300 and 500 ng mL À1 , on the assumption of a hematocrit of 40%; drug concentrations in plasma were not confirmed with LC-MS/MS in this part of the study. For the second part of the study, we recruited 35 patients taking dabigatran etexilate (Pradaxa) because of AF for venous blood sampling (at any time in relation to capsule intake). Samples from 10 healthy blood donors (other than those in the in vitro study) served as control samples.
ROTEM
ROTEM measurements were performed at the Department of Transfusion Medicine at Karolinska University Hospital with ROTEM delta (Tem International, Munich, Germany).
Blood was collected in 3.2% citrate tubes (Becton Dickinson, Franklin Lakes, NJ USA; 4.5 mL) with a routine vacutainer technique. We used the commercially available Ex-tem TF trigger as well as a thrombin-based trigger developed by us. The thrombin trigger was prepared from bovine thrombin (T7513; Sigma Aldrich, St.
Louis, MO, USA). It was delivered as a lyophilized powder and stored at À 20°C until preparation. In a first step, the thrombin was reconstituted with distilled water at a concentration of 250 U mL
À1
, and stored in aliquots at À 80°C. Phospholipids containing highly purified phosphatidylcholine (42 mol%), phosphatidylserine (28 mol%) and sphingomyelin (30 mol%) were purchased from Rossix (M€ olndal, Sweden), and acquired as an emulsion of phospholipids in Tris buffer at a concentration of 250 lM and stored at 2-8°C. Both triggers were further diluted (with distilled water and Tris buffer, respectively) before each day's experiments, and were added separately to the ROTEM cup to give final concentrations in the cup of 2 IU mL À1 (thrombin) and 2 lM (phospholipids). The concentrations of thrombin and phospholipids were chosen to obtain a CT similar to that obtained with Ex-tem in healthy donors. The trigger solution volume used was 20 lL, and the whole blood volume in the test cup was 300 lL. All samples were recalcified with the commercially available calcium solution Star-tem (20 lL) before analysis. On the basis of results from our previous studies, the only variable registered was CT [33] . The reproducibility of the two triggers was similar. Thus, the intra-assay coefficients of variation for CT were 8% (95% confidence interval [CI] 3-13%) for thrombin and 10% (95% CI 8-13%) for Ex-tem, based on blood samples from five different healthy subjects, with each sample being analyzed in quadruplicate.
The difference in CT obtained in test cups with and without added idarucizumab was calculated and expressed as a variable, i.e. CT diff .
In order to decrease the time from blood sampling to test results being obtained, we optimized the performance of the method, and then employed our 'optimized assay' in 10 dabigatran patients. Thus, ROTEM measurements were performed instantly after blood sampling, while still allowing the sample to incubate at 37°C for 5 min. In this set-up, we also had to include 5 min for transportation of samples to the laboratory.
Statistical analysis
Data are expressed as both median and maximum and minimum values (range), and mean with a 95% CI. For comparison between different concentrations in the in vitro study, we used repeated measures ANOVA, and for post hoc testing we used Tukey's multiple comparisons. For comparison between patients and healthy controls, we used independent samples t-tests (variables were normally distributed according to the Shapiro-Wilks test). Analysis of the receiver operating characteristic (ROC) curve was used to evaluate CT and CT diff with maximum specificity and sensitivity for discrimination between patients receiving and not receiving dabigatran, and is presented with a 95% CI. Statistical analyses were performed and figures were created with GRAPHPAD PRISM version 7 (GraphPad Software, La Jolla, CA, USA) and IBM SPSS version 22 (IBM, Armonk, NY, USA).
Results
Measurements of dabigatran effects in vitro
Thrombin CT was concentration-dependently prolonged by dabigatran (Fig. 1A) , and, at the lowest concentration tested (20 ng mL À1 ), dabigatran caused significant CT prolongation (P < 0.01). With the Ex-tem trigger, however, the sensitivity to dabigatran was lower, and a significant difference from control was observed at dabigatran concentrations of ≥ 50 ng mL À1 (P < 0.05), and with a flatter concentration-CT curve than with the thrombinbased trigger (Fig. 1B) . We also measured CT in samples without and with added idarucizumab, in order to investigate the potential reversibility of dabigatran present in the blood. The difference in CT (CT diff ) was calculated, and we found that, as expected, CT diff also increased in a concentration-dependent fashion with increasing dabigatran concentrations (Fig. 1C,D) . Notably, when the thrombin-based trigger was used, an effect of idarucizumab was already obvious at the lowest dabigatran concentration tested (20 ng mL À1 ; Table 1 .
As can be seen from Table 1 and Fig. 1 , there was profound inhibition of the dabigatran anticoagulant effect by idarucizumab. There were small or no differences in CT in samples with different dabigatran concentrations in the presence of idarucizumab with both Ex-tem and thrombin triggers. This reflects complete reversal of the dabigatran drug effects by 1 mg mL À1 idarucizumab within the range of the dabigatran concentrations tested. ). We measured CT in the presence of the two different triggers, without and with the addition of idarucizumab.
As in the in vitro experiments, we calculated CT diff . For comparison, we also performed measurements in whole blood from 10 healthy controls (two women and eight men with a median age of 51 years [range, 30-74 years]) free from any drug treatment.
ROTEM variables in relation to plasma dabigatran concentrations as assessed with LC-MS/MS are presented graphically in Fig. 2A -F, and numerically in Table 2 . Thrombin CT was significantly longer in samples from patients receiving dabigatran than in samples from controls (P < 0.01). Notably, CT in patient samples did not overlap with CT in samples from controls, and the only patient sample with a value close to that of control samples had a very low dabigatran plasma concentration (9 ng mL À1 ; Fig. 2A ). Ex-tem CT was also significantly longer in patient samples than in samples from controls (P < 0.01), but the discrimination between patient and control samples was not complete. Thus, in three patient samples, CT overlapped with CT in controls, and was within the reference interval provided by the manufacturer (38-79 s) . It is of note that these patient samples were not those with the lowest dabigatran concentrations; the actual dabigatran plasma concentrations were 30, 34 and 56 ng mL À1 ( Fig. 2A,B) .
Furthermore, we divided our patient sample material by using a cut-off for dabigatran concentration of 20 ng mL
À1
: that is, CT when the plasma dabigatran concentration of < 20 ng mL À1 versus CT when the plasma dabigatran concentration was > 20 ng mL
. Between these two groups, there was no overlap in CT data, for either thrombin CT or thrombin CT diff , whereas, for Extem CT and Ex-tem CT diff , there were some overlapping CT measurements ( Fig. 2 ; Table 2 ). This is further highlighted by the ROC curve and the calculation of positive predictive value (PPV) and negative predictive value (NPV) shown in Table 3 . In this sample material, thrombin CT and CT diff yielded an area under the curve of 1.0, a sensitivity and specificity of 100%, and a PPV and NPV of 100%, whereas Ex-tem CT and CT diff were slightly less sensitive.
In 10 patients, ROTEM analyses were performed as rapidly as possible. In these, data on thrombin analyses, with and without added idarucizumab, were available within 15 min from sampling.
Discussion
We applied a modified ROTEM-based approach to increase the test sensitivity and rapidly detect the anticoagulant effects of dabigatran in whole blood samples. This set-up could be valuable in emergency situations, such as when an acute surgical intervention is needed, prior to thrombolysis in patients receiving dabigatran presenting with acute ischemic stroke, or in the bleeding patient [3] . Indeed, there is now a highly efficient antidote to be used in patients taking dabigatran in these emergency settings [6] .
We used a thrombin-based trigger to increase the sensitivity of the method, because dabigatran acts specifically by inhibiting thrombin through binding to its catalytic site [34] . This trigger was compared with the commercially available TF-based trigger Ex-tem in whole blood samples in vitro at a wide range of dabigatran concentrations, and in samples from patients receiving treatment with dabigatran etexilate. It is of note that the dependence of the trigger has been shown by others in whole blood assays of direct oral activated factor X inhibitors [15] . Additionally, we performed measurements without and with incubation with the dabigatran antidote idarucizumab, which inhibits the effects of both dabigatran and its acylglucuronic metabolites [35] . This approach was aimed at revealing possible reversible effects of the antidote, and it should also increase the sensitivity in detecting the presence of the drug, as idarucizumab does not influence hemostasis [6] .
In studies in vitro, we found that, with the thrombinbased trigger, the anticoagulant effects of dabigatran can be detected down to a concentration of 20 ng mL À1 , whereas, with the Ex-tem trigger, the lower detection limit is higher, being 50 ng mL À1 . In 35 patients receiving dabigatran treatment, the method detected patients with clinically significant dabigatran concentrations (> 20 ng mL À1 ) with high sensitivity and specificity, albeit with wide CIs, reflecting the relatively low number of patients investigated. Results were obtained within 15 min, which, in our set-up, included a 5-min walk to transport samples to the laboratory. Thus, if the test is performed at the bedside, data may be obtained in an even shorter time.
In a previous study, we found a strong correlation between the ROTEM variable CT and dabigatran concentration, but, with dabigatran concentrations of < 100 ng mL À1 , CTs were close to or within the reference interval provided by the manufacturer [33] . As dabigatran concentrations between 20 ng mL À1 and 100 ng mL À1 still may have significant anticoagulant effects, a rapid and reliable method for detecting dabigatran in this concentration range would be valuable in acute situations. Indeed, in samples from patients receiving dabigatran treatment, we can -by measuring thrombin CT -detect dabigatran effects at concentrations of > 20 ng mL À1 .
Notably, the only patient with a thrombin CT close to the control value was a patient with a very low dabigatran concentration (9 ng mL
À1
). In contrast, when we used Ex-tem CT measurements on samples with concentrations of < 100 ng mL À1 , several measurements were within the ROTEM reference interval. We performed . This is in the very low concentration range in AF patients receiving dabigatran, and confers less protection against thromboembolism and a lower risk of bleeding [36] ; also, it has been suggested by others to have low anticoagulant effects in vivo [37] . The data showed 100% sensitivity and 100% specificity for thrombin CT versus 85% sensitivity and 100% specificity for , but spread on the x-axis to make all data points visible. (E, F) Thrombin (E) and Ex-tem (F) difference in clotting time without versus with IDZ (CT diff ) in the same samples. Dabigatran concentrations in patient samples were determined with liquid chromatography with tandem mass spectrometry [7] .
Ex-tem CT. Our data compare favorably with those obtained with viscoelastic assays employing another thrombin trigger, i.e. ecarin. In a study of the Eca-tem [38] , there was an overlap between patients with and without clinically relevant dabigatran concentrations; similar overlaps were observed between patients receiving dabigatran and controls for the new TEG 6s instrument [24] .
We analyzed all samples with and without the antidote idarucizumab, and with this approach we could study thrombin-induced coagulation with ROTEM in dabigatran samples, as it would be in the absence of dabigatran, thus reflecting the 'non-anticoagulated hemostasis' of the dabigatran-treated patient. In the in vitro study, in which samples were spiked with increasing concentrations of dabigatran, CT was prolonged in a concentration-dependent manner. This effect was completely reversed by addition of idarucizumab throughout the dabigatran concentration range investigated (20-500 ng mL
). We calculated the difference in CT for measurements performed in samples without and with the addition of idarucizumab, as a variable to reflect the dabigatran effect, i.e. CT diff . As the antidote binds to dabigatran with high affinity and specifically blocks its thrombin-inhibiting effects, a significant difference between these two measurements should indicate the specific effect that dabigatran exerts on CT, similarly to the principle of the ROTEM Hep-tem assay [39] . This could be a robust and useful variable for detecting the effect of dabigatran present in acute samples from patients with trauma and major bleeding who could have other acquired coagulation abnormalities affecting viscoelastic test results [40, 41] .
Limitations
Dabigatran plasma concentrations in the in vitro spiking experiments were based on calculations and were not verified with LC-MS/MS. Supratherapeutic levels of dabigatran were not tested in these experiments. Thrombin-and Ex-tem CTs were generally longer in the patient-control sample study than in the controls of the in vitro study. The reason for this is unclear, but may involve differences in experimental set-up; timedependent effects (prolonged experiments) and/or effects caused by solvents (DMSO and acetonitrile) may have influenced in vitro measurements [42, 43] . CIs of the ROC analyses performed in patient samples are wide, reflecting a relatively low number of patients in the study. An expanded and more thorough validation of the method is necessary before this test can be used routinely in the clinic.
Conclusion and implications
This proof-of-concept study has demonstrated that ROTEM with a thrombin-based trigger is more sensitive for detecting the anticoagulant effects of dabigatran 
